Showing results (21-30 of 37) with videos related to
Sort By:
Pageof 4
NPJ Vaccines|December 26, 2025
Influenza vaccination post-COVID-19 expands vaccine-specific effector CD4 T-cells and Tregs under positive influence of host trained innate immunityHima Bindhu, Srabanti Rakshit, Vasista Adiga, et al.Ebiomedicine|July 7, 2026
Transcriptomics of type 1 diabetes progression: a validation study in newly diagnosed patientsTomi Suomi, Inna Starskaia, Omid Rasool, et al.Journal of Medical Virology|July 21, 2022
Concordance of B- and T-cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19Marc F Österdahl, Eleni Christakou, Deborah Hart, et al.Diabetes, Obesity & Metabolism|March 13, 2026
An international consensus on screening and monitoring early-stage type 1 diabetes: A roadmap to European implementationSufyan Hussain, Timothy Tree, Chantal Mathieu, et al.Cell Reports. Medicine|June 5, 2024
A set of circulating microRNAs belonging to the 14q32 chromosome locus identifies two subgroups of individuals with recent-onset type 1 diabetesGuido Sebastiani, Giuseppina Emanuela Grieco, Marco Bruttini, et al.Contemporary Clinical Trials Communications|February 7, 2025
Anti-viral action against type 1 diabetes autoimmunity: The GPPAD-AVAnT1A study protocolSandra Hummel, Alexandra Käßl, Stefanie Arnolds, et al.Cancer Research Communications|February 24, 2023
Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with CancerDuncan R McKenzie, Rosalind Graham, Thomas Lechmere, et al.Ebiomedicine|July 12, 2020
Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trialWilliam Camu, Marius Mickunas, Jean-Luc Veyrune, et al.BMJ Open|October 19, 2021
Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocolJohn W Gregory, Kymberley Carter, Wai Yee Cheung, et al.Annals of the New York Academy of Sciences|May 21, 2024
Pharmacometabolomics applied to low-dose interleukin-2 treatment in amyotrophic lateral sclerosisHugo Alarcan, Clément Bruno, Patrick Emond, et al.Pageof 4